A phase I, open-label, dose-escalation study of AQ4N (banoxantrone) administered intravenously in patients with advanced malignancies

Trial Profile

A phase I, open-label, dose-escalation study of AQ4N (banoxantrone) administered intravenously in patients with advanced malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2006

At a glance

  • Drugs Banoxantrone (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Transcept Pharmaceuticals Inc
  • Most Recent Events

    • 08 Nov 2006 Status change
    • 29 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top